QTc prolongation: Chlorpromazine and high-dosage olanzapine [1]

Canadian Journal of Psychiatry

Volumn 48, Issue 5, 2003, Pages 348-

  Gurovich, Irina ^a   Vempaty, Anitha ^a   Lippmann, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; OLANZAPINE; QUETIAPINE;

AGE DISTRIBUTION; AGED; CASE REPORT; CIRCADIAN RHYTHM; CLINICAL FEATURE; DRUG MEGADOSE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART RATE; HUMAN; LABORATORY TEST; LETTER; LONG QT SYNDROME; METABOLIC DISORDER; QT INTERVAL; SCHIZOAFFECTIVE PSYCHOSIS; SEX DIFFERENCE; ST SEGMENT; T WAVE;

EID: 0037594766     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800513     Document Type: Letter

References (7)

1. Victor W, Vieweg R. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J Clin Psychiatry 2002;63 (Suppl 9):18-24.
2. Tan HL, Hou CJ, Lauer MR, and others. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995;122:701-14.
3. Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002;63(Suppl 9):12-6.
4. Czekalla J, Beasley CM, Deelva MA, and others. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001;62:191-8.
5. Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry 2001;62 (Suppl 22):35-40.
6. Gupta N, Malhotra P. Olanzapine: a proarrhythmic drug? [letter]. Can J Psychiatry 2002;47:683-4.
7. Bouchard RH, Demers MF, Simoneau I, and others. Atypical antipsychotics and cardiovascular risk in schizophrenic patients [letter]. J Clin Psychopharmacol 2001;21:110-11.